Fosinopril – a drug of choice in chronic heart failure prevention and treatment

Abstract

Aim. To study ACE inhibitor fosinopril effects on remodeling, diastolic filling of left and right ventricles (LV, RV), ectopic myocardial activity, heart rate variability, endothelial function, and microcirculation in patients with arterial hypertension (AH) and LV diastolic dysfunction (LVDD). To study fosinopril effects on clinical status, central hemodynamics, remodeling, LV and RV diastolic filling in patients with chronic heart failure (CHF) and LV systolic dysfunction (LVSD). Material and methods. In total, 40 patients with Functional Class II-IV CHF (NYHA), and LV ejection fraction below 40%, as well as 72 patients with AH and LVDD, were examined. Echocardiography, 24-hour ECG monitoring, duplex ultrasonography, laser Doppler flowmetry were performed. Results. In patients with CHF and LVSD, fosinopril treatment improved clinical status, central hemodynamics, remodeling parameters, normalized LV and RV diastolic filling. In patients with AH and LVDD, the drug beneficially influenced heart remodeling, LV and RV diastolic filling, endothelial function, microcirculation, as well as reduced sympathetic tonus and ectopic myocardial activity, decreasing sudden arrhythmic death risk. Conclusion. Fosinopril is a drug of choice in CHF and LVSD treatment, as well as for CHF prevention in patients with AH and LVDD.

Keywords

• фозиноприл
• ремоделирование
• диастолическая функция
• вариабельность сердечного ритма
• микроциркуляция
• хроническая сердечная недостаточность